We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.
An abstract is not available for this content so a preview has been provided. As you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
(1)Boot, Ede Haan, LMassive increase in serum creatine kinase during olanzapine and quetiapine treatment, but not during treatment with clozapine. Psychopharmacology (Berl)2000; 150:347–8CrossRefGoogle Scholar
(2)
(2)Meltzer, HYSerum creatine phosphokinase in schizophrenia. Am J Psychiatry1976;133:192–197.Google Scholar
(3)
(3)Meltzer, HYSkeletal muscle necrosis following membraneactive drugs plus serotonin. J Neurol Sci1976;28:41–56CrossRefGoogle ScholarPubMed
(4)
(4)Meltzer, HYRoss-Stanton, JSchlessinger, S.Mean serum creature kinase activity in patients with functional psychoses. Arch Gen Psychiatry1980;37:650–655.CrossRefGoogle Scholar
(5)
(5)Meltzer, HYCola, PAParsa, MMarked elevations of serum creatine kinase activity associated with antipsychotic drug treatment. Neuropsychopharmacology1996;15:395–405CrossRefGoogle ScholarPubMed
(6)
(6)Meltzer, HYMassive serum creatine kinase increases with atypical antipsychotic drugs: what is the mechanism and the message?Psychopharmacology (Berl) 2000;150:349–50.CrossRefGoogle ScholarPubMed
(7)
(7)Reznik, IVolchek, LMester, RKotler, MSpivak, BWeizman, A et al. Myotoxicity and neurotoxicity during clozapine treatment. Clin Neuropharmacol2000;23:276–80CrossRefGoogle ScholarPubMed
(8)
(8)Scelsa, SNSimpson, DMMcQuiston, HL et al. Clozapineinduced myotoxicity in patients with chronic psychotic disorders. Neurology1996;47:1518–1523.CrossRefGoogle Scholar
Comments
No Comments have been published for this article.